Birx Deborah 4

What Happened
Deborah Birx, CEO of Armata Pharmaceuticals (ARMP), received a grant/award of 421,226 derivative shares (recorded as an award of stock options) on March 9, 2026. The Form 4 lists the per-share amount as $0.00 and classifies the transaction as a derivative award (transaction code A). This is an executive equity grant, not a market purchase or sale — no cash was exchanged at the time of grant.

Key Details

• Transaction date: 2026-03-09; Form 4 filed: 2026-03-11 (Accession 0001104659-26-026582).
• Reported price: $0.00 per share on the Form 4 (derivative award).
• Shares/units granted: 421,226 (derivative - stock options).
• Shares owned after transaction: not specified in the provided excerpt.
• Vesting (footnote F1): 25% of the stock options vest each March 9 of 2027, 2028, 2029 and 2030, subject to continuous service through each vesting date.
• Timeliness: Filing appears timely (filed two days after the reported transaction).

Context
This is a grant of stock options (a potential future right to receive shares) that vests over four years; it does not represent an immediate open-market purchase or sale. Such grants are routine for executive compensation and signal future potential dilution rather than an immediate change in insider ownership or market action. For full economics (exercise price, expiration, tax withholding, or other terms) check the company’s proxy, award agreements, or press release; the Form 4 notes the grant and vesting schedule but lists $0.00 per share in the reported field.